학술논문
Bevacizumab: Is the lower the better for glioblastoma patients in progression?
Document Type
Article
Author
Source
Bulletin du Cancer; December 2018, Vol. 105 Issue: 12 p1135-1146, 12p
Subject
Language
ISSN
00074551; 17696917
Abstract
Based on the radiological responses obtained with a schedule of ten mg/kg every two weeks bevacizumab was approved by the FDA for recurrent glioblastomas. Due to the negative results concerning overall survival of patients receiving bevacizumab, the European application was rejected. Despite this, many centers apply an off-label prescription. Our aim was to evaluate the safety and efficacy of schedules of low doses of bevacizumab.